



UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 20 2010

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

Office of Regulatory Policy  
Food and Drug Administration  
10903 New Hampshire Ave., Bldg. 51, Rm. 6222  
Silver Spring, MD 20993-0002

Attention: Beverly Friedman

Dear Ms. Axelrad:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 6,028,071. The application was filed on November 19, 2009, under 35 U.S.C. § 156.

The patent claims the human drug product FOLOTYN®, a method of using FOLOTYN® and a pharmaceutical composition comprising FOLOTYN®. FOLOTYN® was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term extension. Thus, a determination by your office of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to the undersigned at (571) 272-7755 (telephone) or (571) 273-7755 (facsimile).

Mary C. Till  
Legal Advisor  
Office of Patent Legal Administration  
Office of the Associate Commissioner  
for Patent Examination Policy

cc: Marina Larson  
Larson & Anderson, LLC  
P.O. Box. 4928  
Dillon, CO 80435-4928

RE: FOLOTYN® (pralatrexate)  
Docket No. FDA-2010-E-0030